Trials / Completed
CompletedNCT02531360
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Molecular NeuroImaging · Academic / Other
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
The overall goal of this imaging trial is to characterize \[18F\]MNI-815, a PET radioligand for imaging Tau.
Conditions
- Alzheimer's Disease (AD)
- Progressive Supranuclear Palsy (PSP)
- Cortical Basal Syndrome (CBS)
- Frontal Temporal Dementia (FTD)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]MNI-815 (MNI-815) | All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition. |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2016-07-01
- Completion
- 2016-08-01
- First posted
- 2015-08-24
- Last updated
- 2016-12-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02531360. Inclusion in this directory is not an endorsement.